Table 5.
Select molecular profiling results for head and neck squamous cell carcinoma case illustration.
| Test | Modality (IHC/ISH/NGS) | Alteration | Interpretation | Drug associations |
|---|---|---|---|---|
| PGP | IHC | 0+ 100% (intensity and cell staining) | Negative | Benefit from taxanes (docetaxel, paclitaxel, and nab‐paclitaxel) |
| SPARC | IHC | 2+ 35% (intensity and cell staining) | Positive | |
| TLE3 | IHC | 2+ 35% (intensity and cell staining) | Positive | |
| TS | IHC | 1+ 1% (intensity and cell staining) | Negative | Benefit from fluoropyrimidines (fluorouracil, pemetrexed) |
| TOPO1 | IHC | 2+ 40% (intensity and cell staining) | Positive | Benefit from camptothecin Derivatives (topotecan, irinotecan) |
| TOP2A | IHC | 1+ 2% (intensity and cell staining) | Negative | Lack of benefit from TOP2A‐targeted agents (doxorubicin) |
| APC | NGS | L1129S | Variant of unknown significance | Clinical trials |
| TP53 | NGS | R213X | Pathogenic mutation | Clinical trials |
Abbreviations: IHC, immunohistochemical; ISH, in situ hybridization; NGS, next‐generation sequencing; PGP, permeability glycoprotein; SPARC, secreted protein acidic and rich in cysteine.